Fibroblast growth factor 21 (FGF21) is an effective metabolic regulator of glucose and lipid homeostasis in the context of insulin resistance, glucose intolerance and dyslipidemia in diabetic rodents and monkeys, and peroxisome proliferator-activated receptor a a (PPARa a) directly induces FGF21 expression in the rodent liver. Recent findings suggest that the effects and regulation of FGF21 qualitatively differ between rodents and humans. Here, we examined the effects of PPARa a and PPARg g agonists on FGF21 mRNA expression in the mouse liver and in cultured hepatocytes. Intraperitoneal injection of both bezafibrate and pioglitazone induced FGF21 mRNA expression in the mouse liver. Rosiglitazone and pioglitazone as well as bezafibrate significantly induced FGF21 mRNA expression in cultured mouse hepatocytes. On the other hand, both rosiglitazone and pioglitazone significantly induced, whereas bezafibrate did not affect FGF21 mRNA expression in the human liver carcinoma cell line HepG2. Bezafibrate significantly induced pyruvate dehydrogenase kinase 4 mRNA expression, suggesting that HepG2 cells are sensitive to bezafibrate like the mouse liver. Our findings suggest that PPARg g-activating antidiabetic drugs such as rosiglitazone and pioglitazone induce FGF21 expression in mouse and human hepatocytes, and that PPARg g rather than PPARa a might play an important role in human FGF21 production.
Fibroblast growth factor 21 (FGF21) is an effective metabolic regulator of glucose and lipid homeostasis in the context of insulin resistance, glucose intolerance and dyslipidemia in diabetic rodents and monkeys. 1) The expression of FGF21 is most abundant in the liver and it is induced by fasting and starvation in a peroxisome proliferator-activated receptor a (PPARa)-dependent manner in rodents. 1) Tentative PPAR responsive elements (PPREs) are located in the promoter regions of both mouse and human FGF21 genes, and hepatic FGF21 mRNA expression is robustly induced by PPARa agonists as well as by fasting and starvation in mice. However, recent findings suggest that the effects and regulation of FGF21 qualitatively differ between humans and animal models. 1) Plasma protein and hepatic mRNA levels of FGF21 are obviously increased over 10-fold by a 24-h fast in mice, 2) whereas serum FGF21 levels are unchanged by a 2-d fast in humans. 3) The administration of PPARa agonists such as GW7647, Wy-14,643 and bezafibrate induce the hepatic FGF21 mRNA expression by 8-to 40-fold in mice, [4] [5] [6] whereas 3 weeks of fenofibrate administration increase plasma FGF21 levels by only 28% in humans. 3) The fold induction of PPARa agonist-dependent FGF21 mRNA expression is relatively small in human, 4, 5) compared with mouse hepatocytes. 7) To our best of our knowledge, PPARg-dependent FGF21 expression in the liver or hepatocytes has not yet been evaluated. The present study examines the effect of PPARg agonists on FGF21 mRNA expression in the mouse liver and in cultured hepatocytes.
MATERIALS AND METHODS
Six-week-old male Slc:ICR mice (Japan SLC Inc., Hamamatsu, Japan) were housed under a 12 h light-12 h dark cycle and given food and water ad libitum. Bezafibrate (Sigma, U.S.A.), rosiglitazone (Cayman Chemical Co., MI, U.S.A.) and pioglitazone (Toronto Research Chemicals Inc., Ontario, Canada) were dissolved in warm (ca. 40°C) sterile corn oil (Sigma) at a concentration of 3 mg/ml and administered as a single intraperitoneal (i.p.) dose of 30 mg/kg body weight. Sterile corn oil served as the control injection. After 4 h, the mice were sacrificed and tissues were dissected, quickly frozen and stored at Ϫ80°C. All animal experiments and handling proceeded under the authorization of the Animal Care and Use Committees of AIST (Permission #2010-020).
Mouse primary hepatocytes were obtained from the Primary Cell Co., Ltd. (Ishikari, Japan) as attached cells in 24well plates in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 U/ml penicillin, 10 mg/ml streptomycin, 0.5 mg/ml insulin, 1 mM dexamethasone, 10 ng/ml epidermal growth factor, 200 mM ascorbic acid, and 10 mM nicotinamide. HepG2 cells were cultured in DMEM (Sigma) supplemented with 10% FBS (Invitrogen) and antibiotics in a 5% CO 2 atmosphere. The cells were incubated with 100 mM of PPAR ligands or vehicle (0.01% dimethyl sulfoxide (DMSO)) for 4 h, washed with ice cold phosphate buffered saline (PBS), then harvested in RNAiso (Takara Bio Inc., Otsu, Japan) and stored at Ϫ80°C.
Total RNA was extracted using RNAiso. Single-strand cDNA was synthesized using the PrimeScript TM RT reagent kit with gDNA Eraser (Takara Bio Inc., Otsu, Japan). Realtime reverse transcription-polymerase chain reaction (RT-PCR) proceeded using the SYBR ® Premix Ex Taq TM II (Takara Bio Inc., Otsu, Japan) using a LightCycler TM (Roche Diagnostics, Mannheim, Germany). The reaction conditions were 95°C for 10 s followed by 45 cycles of 95°C for 5 s, 57°C for 10 s and 72°C for 10 s. The sequence of primer pairs were as follows: mouse FGF21, 5Ј-ATGGAATGGAT-GAGATCTAGAGTTGG-3Ј and 5Ј-TCTTGGTCGTCATCT-GTGTAGAGG-3Ј; mouse pyruvate dehydrogenase kinase 4 (PDK4), 5Ј-CACATGCTCTTCGAACTCTTCAAG-3Ј and 5Ј-TGATTGTAAGGTCTTCTTTTCCCAAG-3Ј; mouse 18S ribosomal RNA (rRNA), 5Ј-GTAACCCGTTGAACCCCA-TT-3Ј and 5Ј-CCATCCAATCGGTAGTAGCG-3Ј; human FGF21, 5Ј-GAGTCAAGACATCCAGGTTCCTG-3Ј and 5Ј-GACTTGTTCCCTGGCAGGTGCAG-3Ј; human PDK4, 5Ј-CTGTCCATGAAGCAGCTACTG-3Ј and 5Ј-TCCACCAA-ATCCATCAGGCTCTG-3Ј; human 18S rRNA, 5Ј-CGGC-GACGACCCATTCGAAC-3Ј and 5Ј-GAATCGAACCCTG-ATTCCCCGT-3Ј. The amount of target mRNA was normalized relative to that of 18S rRNA.
RESULTS AND DISCUSSION
Intraperitoneal injection of both bezafibrate and pioglitazone significantly induced, whereas that of rosiglitazone did not affect FGF21 mRNA expression in the mouse liver ( Fig.  1 ). Rosiglitazone and pioglitazone as well as bezafibrate significantly induced FGF21 mRNA expression in cultured mouse hepatocytes ( Fig. 2A) . On the other hand, both rosiglitazone and pioglitazone significantly induced, whereas bezafibrate did not affect FGF21 mRNA expression in the human liver carcinoma cell line HepG2 (Fig. 2B ). However, bezafibrate significantly induced pyruvate dehydrogenase kinase 4 (PDK4) mRNA expression, suggesting that HepG2 cells are sensitive to bezafibrate like the mouse liver. Our findings suggest that PPARg-activating antidiabetic drugs such as rosiglitazone and pioglitazone induce FGF21 expression in both mouse and human hepatocytes, and that PPARg plays a critical role in the regulation of FGF21 expression especially in the human liver.
High levels of PPARg are expressed in the fatty liver induced by a high-fat or ketogenic diet, the latter of which induces FGF21 expression in a PPARa-independent manner. 7, 8) FGF21 seems to be a novel biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 9) Therefore, PPARg activation might be responsible for hepatic FGF21 expression under conditions of NAFLD or NASH. On the other hand, Gälman et al. reported that serum levels of FGF21 varied 250-fold among 76 healthy individuals and did not relate to age, gender, body mass index, serum lipids, or plasma glucose. 3) Further elucidation of the molecular mechanism regulating FGF21 expression by thiazolidinediones especially in human tissues will be of great interest. 
